Gujarat Inject (Kerala) Ltd

The next results date for Guj. Inject(Ker) is 13 November 2025.

Guj. Inject(Ker) has shown significant growth, with net sales increasing from 0.02 crore in March 2022 to 19.05 crore in March 2025, alongside a turnaround in profitability, achieving a profit after tax of 1.02 crore and an EPS rise to 0.7 during the same period. The company has transitioned from losses to consistent profitability, reflected in improved operating margins.

Guj. Inject(Ker) will declare its results on 14 August 2025.

As of 24th July, Gujarat Inject (Kerala) Ltd has a market capitalization of 35.00 Cr, classifying it as a Micro Cap company, with recent Net Sales of 19.05 Cr and a Net Profit of 1.01 Cr; specific values for Shareholder's Funds and Total Assets are unavailable.

Gujarat Inject (Kerala) Ltd is a micro-cap pharmaceutical company specializing in I.V. fluids, with a market cap of INR 34 Cr and reported net sales of 42 Cr and net profit of 1 Cr for the quarter ending March 2025. The company has no debt and a dividend yield of 0%.

The top shareholders of Guj. Inject(Ker) are mainly individual investors, holding 83.95% of shares, with Jignesh Shivlal Makasana as the largest public shareholder at 11.95%. There are no institutional holdings or pledged promoter shares.

As of May 22, 2025, the technical outlook is mildly bullish, supported by daily moving averages and KST indicators, despite mixed signals from the Bollinger Bands and a bearish weekly MACD.

As of May 22, 2025, the technical outlook is mildly bullish, supported by daily moving averages and KST indicators, despite mixed signals from the Bollinger Bands and a bearish weekly MACD.

Guj. Inject(Ker) has shown significant financial growth, with net sales increasing from Rs 0.02 crore in March 2022 to Rs 19.05 crore in March 2025, alongside a turnaround from operating losses to an operating profit of Rs 1.26 crore. Profit after tax reached Rs 1.02 crore, and earnings per share rose to Rs 0.7, reflecting improved profitability and operational efficiency.

Peers of Guj. Inject(Ker) include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. Sun Pharma, Cipla, and Dr Reddy's Labs show excellent management and growth, while Guj. Terce Labs and others have below-average ratings.

As of March 2022, the management team of Guj. Inject(Ker) includes Murli Shivshankaran Nair (Whole Time Director & CFO), Reena Mahatma (Director), and independent directors Narayansinh Padudansinh Chauhan and Gautam Keshavlal Chauhan.

As of 05-Jun, Gujarat Inject (Kerala) Ltd's stock price is Rs 22.85, down 4.99%, with a total decline of 19.26% over the last five days. Despite trading above some moving averages and increased investor participation, it has significantly underperformed compared to the Sensex and its sector.